Showing 1 posts of 1 posts found.
AstraZeneca is betting big on lung disease specialist Pearl Therapeutics as it looks to spend $1.2 billion to acquire the …
NHS England approves delayed-release treatment for rare kidney disease
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
Functional lung imaging offers new possibilities for respiratory care
Five Facts about cardiovascular disease
Data integrity: the keystone for AI adoption, patient safety and organisational reputation